Gastroenterology and Hepatology

Immunotherapy in GI Cancer Treatment

Immunotherapy has emerged as a groundbreaking approach in the treatment of gastrointestinal (GI) cancers, including colorectal cancer, esophageal cancer, gastric cancer, and liver cancer. Unlike traditional treatments such as chemotherapy and radiation, which target cancer cells directly, immunotherapy aims to enhance the body's immune system to recognize and attack cancer cells more effectively.

One of the most promising immunotherapies in GI cancer treatment is checkpoint inhibitors. These drugs, such as pembrolizumab and nivolumab, block immune checkpoints like PD-1 and PD-L1, which cancer cells exploit to evade immune detection. By inhibiting these checkpoints, the immune system is activated to target and destroy cancer cells.

Another promising approach is adoptive T-cell therapy, where a patient's own T-cells are extracted, modified, and reintroduced to fight cancer. Cancer vaccines, designed to stimulate an immune response against specific tumor markers, are also being explored.

Immunotherapy has shown significant success in advanced stages of GI cancers, particularly in patients with microsatellite instability-high (MSI-H) or mismatch repair deficiency (dMMR) tumors. These cancers tend to respond well to immune checkpoint inhibitors, offering hope for patients with previously limited treatment options.